For KRAS-Mutant CRC: PD-1 Combination Trial with cobimetinib (MEK inhibitor)

[DK37]

A new paper came out today for those of you that are KRAS-mutant. For the first time, it was shown that KRAS-mutations directly impact the immune system's response to tumors in preclinical models of KRAS-mutant CRC by means of increasing immunosuppressive “regulatory T-cells”(abreviated "Tregs") Tregs have already been shown to be a trick used by CRC tumors to suppress the immune system.

What does that mean? It means that there is a chance that using “MEK inhibitors” (which impact the KRAS pathway) as a co-therapy may help get PD-1 activity in KRAS-Mutant patients. So for KRAS-mutant patients, here is another immunotherapy trial to keep an eye on... (Cobimetinib is a MEK inhibitor) - trial sites nationwide. The trial has been going on long enough maybe they'll release some preliminary data at ASCO in June?? https://clinicaltrials.gov/ct2/show/NCT ... 896&rank=1 Today’s preclinical paper: http://cancerimmunolres.aacrjournals.or ... 1.abstract . A paper from about a year ago on synergy between MEK inhibition & PD-1 inhibition in a CRC model (CT26): http://clincancerres.aacrjournals.org/c ... 1639.short

-DK

[Nik Colon]

So, does that include MSS

[Nik Colon]

Oops, dp

[Nik Colon]

Oops, TP sorry, stupid phone!

[DK37]

So, does that include MSS

Hi Nik-

Based upon the clinicaltrials.gov page - the trial appears open to MSS-CRC but I haven't called to confirm-

-DK

[Nik Colon]

So, does that include MSS

Hi Nik-

Based upon the clinicaltrials.gov page - the trial appears open to MSS-CRC but I haven't called to confirm-

-DK

Thanks.

[DK37]

I would pay particular attention to this trial, especially if you are KRAS-mutant.

-DK